Will Lonza stock go up?

According to Danelfin AI, Lonza has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (44.80%) is -4.80% vs. the average probability (49.60%) of all European stocks.

Is it a good time to buy, sell, or hold Lonza stock right now?

Lonza has today a Sell rating (AI Score 3/10), according to Danelfin AI. Its probability of beating the market in 3 months (44.80%) is -4.80% vs. the average probability (49.60%) of all European stocks, based on our AI-powered analysis. You can find more details on whether Lonza stock is a good buy .

What is going on with Lonza stock in the last 3 months?

The Lonza stock performance in the last quarter has been +10.23%.

Does Lonza offer dividend payments?

Yes, Lonza stock dividend yield is 0.44%.

What is the current market capitalization of Lonza?

Lonza's market cap is CHF 38.34B, as of 2026-07-03 08:00.

Lonza Group AG (LONN.SW) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

LONN.SW AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Profitability+1.29%
Profitability and operating efficiency metrics
Valuation+0.62%
How the stock is priced relative to its fundamentals
Growth+0.60%
Expected pace of revenue and earnings expansion
Earnings Quality+0.56%
Stability and reliability of reported earnings
Size & Liquidity+0.21%
Company size and trading liquidity

Sentiment-3.47%
How analysts and the market view the stock
Momentum-2.05%
Direction and strength of recent price movements
Volatility-1.94%
How much the stock price tends to fluctuate
Financial Strength-0.62%
Balance sheet strength and financial resilience

LONN.SW probability advantage of beating the market (3M):

-4.80%

AI Score

Sell

Lonza (LONN.SW) has an AI Score of 3/10 (Sell) because, according to an overall analysis, it has a probability advantage of -4.80% of beating the market (STOXX 600) in the next 3 months. This advantage is calculated as the difference between the average probability of any European stock (49.60%) and the probability of LONN.SW (44.80%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any European stock of beating the market (3M)49.60%
LONN.SW probability advantage of beating the market (3M)-4.80%
LONN.SW probability of beating the market (3M)44.80%

LONN.SW probability advantage of beating the market (3M): -4.80%

The AI-powered overall analysis of Lonza (LONN.SW) is based on the 33 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 24 months (alpha signals). These alpha signals explain the probability advantage of LONN.SW:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	Industry (GICS)	Life Sciences Tools & Services	N/A	-3.60%
Technical	Avg. Last Decile Drawdown (1Y)	-0.06		-0.95%
Technical	ATR (180d Volatility)	11.81		-0.68%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+0.62%
Fundamental	Diluted EPS	13.51		+0.60%
Fundamental	Consolidated Net Income / Loss	909M		+0.56%
Technical	Distance from KAMA (100d)	0.10%		-0.53%
Technical	Alpha YTD	-0.04%		-0.49%
Fundamental	Cash & Short-Term Investments YoY Growth	-0.58%		-0.48%
Fundamental	Provision For Income Taxes YoY Growth	2.20%		+0.44%
Technical	Upgrade to unlock			-0.44%
Fundamental	Upgrade to unlock			+0.39%
Technical	Upgrade to unlock			-0.32%
Sentiment	Upgrade to unlock			+0.28%
Sentiment	Upgrade to unlock			-0.22%

Rest of Alpha Signals: +0.02%

LONN.SW probability advantage of beating the market (3M)Total:-4.80%
LONN.SW AI Score

Significant changes Vs previous day

LONN.SW Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:CHF 564.60
Horizon: 3 months
Stop Loss:CHFXXXXXPro (XXXXXPro)
Take Profit:CHFXXXXXPro (XXXXX
Pro
)

LONN.SW Proven Sell Signal & Price Forecast

This is the price chart for LONN.SW from January 2, 2026 until today. The chart indicates, in red, the 7 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

LONN.SW Average Past Performance & Loss Rate

Three months after its 132 Sell signals since July 2026, LONN.SW had an average performance of xxxxxx and a xxxxxx Loss rate (negative performance).

132 Past LONN.SW Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+3.16%
Average Alpha				+6.60%
Loss Rate (% Negative Perf.)				50.00%
% Negative Alpha				0.00%

LONN.SW Frequently Asked Questions

Will Lonza stock go up?
According to Danelfin AI, Lonza has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (44.80%) is -4.80% vs. the average probability (49.60%) of all European stocks.
Is it a good time to buy, sell, or hold Lonza stock right now?
What is going on with Lonza stock in the last 3 months?
Does Lonza offer dividend payments?
What is the current market capitalization of Lonza?

Lonza Group AG Company Profile

Lonza Group AG (LONN.SW) is a premier global partner to the pharmaceutical, biotech, and nutrition industries, operating as a leading contract development and manufacturing organization (CDMO). The company provides an extensive suite of services that span the entire product lifecycle, from early-stage research and development through to commercial manufacturing. Lonza leverages its profound scientific expertise and advanced technological platforms to support clients in bringing innovative therapies and health products to market, playing a critical role in the global life sciences ecosystem.

Lonza's integrated offerings encompass a broad spectrum of modalities, including mammalian and microbial biopharmaceuticals, small molecules, and cutting-edge cell and gene therapies. This comprehensive capability allows Lonza to serve a diverse client base, ranging from emerging biotechs to large pharmaceutical companies. The company's commitment to quality, regulatory excellence, and operational efficiency ensures reliable and scalable production, making it a trusted partner for complex and high-value therapeutic programs. Lonza's strategic value is further enhanced by its ability to provide end-to-end solutions, streamlining the development and manufacturing process for its customers.

The company's market position is underpinned by its continuous investment in state-of-the-art facilities and advanced technologies, anticipating and responding to the evolving demands of the healthcare sector. Lonza is at the forefront of addressing the increasing need for specialized and personalized medicines, including advanced therapies that require highly sophisticated manufacturing processes. This forward-looking approach, coupled with a robust project pipeline, positions Lonza to capitalize on the sustained growth in biopharmaceuticals and the broader trend towards outsourcing specialized manufacturing capabilities. Its focus on innovation and sustainable practices reinforces its long-term growth trajectory.

Lonza's operational strength is characterized by its global network of manufacturing sites and research centers, strategically located to serve key markets worldwide. This extensive footprint, combined with a deep understanding of regional regulatory landscapes, enables efficient and compliant delivery of services. The company's financial performance reflects its critical role in the healthcare supply chain, offering a compelling investment proposition rooted in essential services for life-saving and life-enhancing products. Lonza's revenue mix is predominantly derived from its Biologics and Small Molecules divisions, with a significant contribution from Cell & Gene Technologies and Nutrition & Consumer Health, and it primarily employs a direct sales model to engage with its global client base across North America, Europe, and Asia.

Sector:
Country:Switzerland
Industry:
Address:Muenchensteinerstrasse 38, Basel
Employees:20,000
Website:lonza.com

Pros

High client switching costs in drug manufacturing

Regulatory barriers to entry in pharmaceutical production

Structural trend of pharmaceutical outsourcing

Diversified client base across therapeutic areas

Specialized capabilities in complex biologics manufacturing

Cons

High capital expenditure for manufacturing facilities

Demand cyclicality from pharmaceutical R&D pipeline

Competitive market for contract manufacturing services

Operational risk from regulatory compliance failures

Exposure to client intellectual property disputes

Company	AI Score	Compare
SDZ.SWSandoz Group AG
XLS.SWXlife Sciences AG
BSLN.SWBasilea Pharmaceutica AG Allschwil
NOVN.SWNovartis AG
SKAN.SWSKAN Group AG

	Company	AI Score	Compare
1	PANG.MCPangaea Oncology SA
2	SFZN.SWSiegfried Holding AG
3	DXRX.LDiaceutics PLC
4	DIM.PASartorius Stedim Biotech SA
5	ERF.PAEurofins Scientific SE
6	BANB.SWBachem Holding AG
7	MLC.IRMalin Corporation PLC
8	CHEMM.COChemometec A/S
9	GUBRA.COGubra A/S
10	HEN.WA

	Company	AI Score	Compare
1	PANG.MCPangaea Oncology SA
2	SFZN.SWSiegfried Holding AG
3	DXRX.LDiaceutics PLC
4	DIM.PASartorius Stedim Biotech SA
5	ERF.PAEurofins Scientific SE
6	BANB.SWBachem Holding AG
7	MLC.IRMalin Corporation PLC
8	CHEMM.COChemometec A/S
9	GUBRA.COGubra A/S
10	HEN.WA

Company	AI Score	Compare
SDZ.SWSandoz Group AG
XLS.SWXlife Sciences AG
BSLN.SWBasilea Pharmaceutica AG Allschwil
NOVN.SWNovartis AG
SKAN.SWSKAN Group AG

LONN.SW Stock AI Analysis

Lonza Group AG

LONN.SW Stock AI Analysis

Lonza Group AG

LONN.SW AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

AI Score Explanation

Generating AI Score explanation

AI Score Alpha Factors

Alpha Signals: What Drives the AI Score

LONN.SW probability advantage of beating the market (3M): -4.80%

LONN.SW Short Trading Parameters

LONN.SW Proven Sell Signal & Price Forecast

LONN.SW Average Past Performance & Loss Rate

LONN.SW Frequently Asked Questions

Will Lonza stock go up?

Is it a good time to buy, sell, or hold Lonza stock right now?

What is going on with Lonza stock in the last 3 months?

Does Lonza offer dividend payments?

What is the current market capitalization of Lonza?

Lonza Group AG Company Profile

Pros

Cons

Pros

Cons

LONN.SW Company Profile Summary

LONN.SW Related Stocks

LONN.SW Top 10 Industry Stocks

Life Sciences Tools & Services

LONN.SW Top 10 Sector Stocks

Health Care

LONN.SW Stock AI Analysis

Lonza Group AG

SWISS EXCHANGE

Will Lonza stock go up?

Is it a good time to buy, sell, or hold Lonza stock right now?

What is going on with Lonza stock in the last 3 months?

Does Lonza offer dividend payments?

What is the current market capitalization of Lonza?

SWISS EXCHANGE

Pros

Cons

LONN.SW Proven Sell Signal & Price Forecast

AI Score Explanation

Generating AI Score explanation